Floatz logo

Imsa101

OligoProgressive Metastatic Disease

University of Texas Southwestern Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

170 Active assets in the OligoProgressive Metastatic Disease cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Imsa101 is also rated in:

OligoprogressiveDormant
CCC
Indicative ·
53 / 100
View asset →
Oligometastatic DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
Solid Tumor, AdultDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →